Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
Adult
Amino Acid Sequence
COVID-19
/ immunology
Cohort Studies
Coronavirus Nucleocapsid Proteins
/ chemistry
Coronavirus OC43, Human
/ genetics
Cross Reactions
/ genetics
Enzyme-Linked Immunosorbent Assay
/ methods
Epitope Mapping
/ methods
Epitopes, B-Lymphocyte
/ immunology
HEK293 Cells
Health Personnel
/ statistics & numerical data
Humans
Protein Domains
SARS-CoV-2
/ genetics
Sequence Homology, Amino Acid
Spike Glycoprotein, Coronavirus
/ genetics
B cells
SARS-CoV-2
antibodies
cross-reactivity
emerging disease
humoral response
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Mar 2022
10 Mar 2022
Historique:
received:
11
01
2022
revised:
08
02
2022
accepted:
21
02
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
The B and T lymphocytes of the adaptive immune system are important for the control of most viral infections, including COVID-19. Identification of epitopes recognized by these cells is fundamental for understanding how the immune system detects and removes pathogens, and for antiviral vaccine design. Intriguingly, several cross-reactive T lymphocyte epitopes from SARS-CoV-2 with other betacoronaviruses responsible for the common cold have been identified. In addition, antibodies that cross-recognize the spike protein, but not the nucleoprotein (N protein), from different betacoronavirus have also been reported. Using a consensus of eight bioinformatic methods for predicting B-cell epitopes and the collection of experimentally detected epitopes for SARS-CoV and SARS-CoV-2, we identified four surface-exposed, conserved, and hypothetical antigenic regions that are exclusive of the N protein. These regions were analyzed using ELISA assays with two cohorts: SARS-CoV-2 infected patients and pre-COVID-19 samples. Here we describe four epitopes from SARS-CoV-2 N protein that are recognized by the humoral response from multiple individuals infected with COVID-19, and are conserved in other human coronaviruses. Three of these linear surface-exposed sequences and their peptide homologs in SARS-CoV-2 and HCoV-OC43 were also recognized by antibodies from pre-COVID-19 serum samples, indicating cross-reactivity of antibodies against coronavirus N proteins. Different conserved human coronaviruses (HCoVs) cross-reactive B epitopes against SARS-CoV-2 N protein are detected in a significant fraction of individuals not exposed to this pandemic virus. These results have potential clinical implications.
Identifiants
pubmed: 35328398
pii: ijms23062977
doi: 10.3390/ijms23062977
pmc: PMC8955325
pii:
doi:
Substances chimiques
Coronavirus Nucleocapsid Proteins
0
Epitopes, B-Lymphocyte
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerio de Ciencia e Innovación
ID : COV20_00679 (MPY 222-20)
Organisme : Ministerio de Ciencia e Innovación
ID : MPY 509/19
Organisme : Ministerio de Ciencia e Innovación
ID : MPY 388/18
Références
EBioMedicine. 2020 Aug;58:102911
pubmed: 32711254
J Infect Dis. 2010 Oct 15;202(8):1171-80
pubmed: 20831383
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Chin Sci Bull. 2003;48(10):941-948
pubmed: 32214698
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
Arch Virol. 2020 Dec;165(12):2829-2835
pubmed: 33000310
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
J Clin Pathol. 2006 May;59(5):468-76
pubmed: 16461566
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Viruses. 2018 May 02;10(5):
pubmed: 29724026
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
Vaccines (Basel). 2020 Jul 20;8(3):
pubmed: 32698423
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Vaccines (Basel). 2021 Jan 11;9(1):
pubmed: 33440622
NPJ Vaccines. 2020 Mar 6;5(1):18
pubmed: 32194995
Elife. 2020 Apr 02;9:
pubmed: 32228860
J Clin Immunol. 2021 Jul;41(5):906-913
pubmed: 33725211
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W429-32
pubmed: 17483518
Virus Res. 2006 Dec;122(1-2):109-18
pubmed: 16942813
Emerg Infect Dis. 2004 Nov;10(11):1947-9
pubmed: 15550204
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Cell Rep Med. 2021 Jan 19;2(1):100189
pubmed: 33495758
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Virus Res. 2006 Dec;122(1-2):119-26
pubmed: 16920216
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2006-2011
pubmed: 32141569
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Nat Biotechnol. 2020 Jul;38(7):789-791
pubmed: 32504046
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292
pubmed: 32445559
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147